A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Clinical trial NCT04148937 · COMPLETED
Trial details
- NCT number
- NCT04148937
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-16
- Primary completion
- 2021-05-12
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.